An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response.
Antibody-based therapies for cancer rely on the expression of defined antigens on neoplastic cells. However, most tumors display heterogeneity in the expression of such antigens. We demonstrate here that antibody-targeted interleukin 2 delivery overcomes this problem by induction of a host immune re...
Na minha lista:
| Publicado no: | Proc Natl Acad Sci U S A |
|---|---|
| Principais autores: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
National Academy of Sciences
1996
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC38833/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8755561/ https://ncbi.nlm.nih.govhttps://doi.org/10.1073/pnas.93.15.7826 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|